Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
PLoS One ; 18(2): e0270388, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36745590

RESUMO

The main objective of this study was to estimate the performance, under local epidemiological conditions, of two in-house ELISA assays for the combined detection of anti-SARS-CoV-2 IgA, IgM, and IgG immunoglobulins. A total of 94 serum samples were used for the assessment, where 44 corresponded to sera collected before the pandemic (free of SARS-CoV-2 antibodies), and 50 sera were collected from confirmed COVID-19 patients admitted to the main public hospital in the city of Valdivia, southern Chile. The Nucleocapsid (Np) and the receptor-binding domain (RBD) proteins were separately used as antigens (Np and RBD ELISA, respectively) to assess their diagnostic performance. A receiver operating characteristic (ROC) analysis was performed to estimate the optical density (OD) cut-off that maximized the sensitivity (Se) and specificity (Sp) of the ELISA assays. Np ELISA had a mean Se of 94% (95% CI = 83.5-98.8%) and a mean Sp of 100% (95% CI = 92.0-100%), with an OD 450 nm positive cut-off value of 0.88. On the other hand, RBD ELISA presented a mean Se of 96% (95% CI = 86.3-99.5%) and a mean Sp of 90% (95% CI = 78.3-97.5%), with an OD 450 nm positive cut off value of 0.996. Non-significant differences were observed between the Se distributions of Np and RBD ELISAs, but the latter presented a significant lower Sp than Np ELISA. In parallel, collected sera were also analyzed using a commercial lateral flow chromatographic immunoassay (LFCI), to compare the performance of the in-house ELISA assays against a commercial test. The LFCI had a mean sensitivity of 94% (95% CI = 87.4-100%) and a mean specificity of 100% (95% CI = 100-100%). When compared to Np ELISA, non-significant differences were observed on the performance distributions. Conversely, RBD ELISA had a significant lower Sp than the LFCI. Although, Np ELISA presented a similar performance to the commercial test, this was 2.5 times cheaper than the LFCI assay (labor cost not considered). Thus, the in-house Np ELISA could be a suitable alternative tool, in resource limited environments, for the surveillance of SARS-CoV-2 infection, supporting further epidemiological studies.


Assuntos
COVID-19 , Humanos , COVID-19/diagnóstico , COVID-19/epidemiologia , SARS-CoV-2 , Imunoglobulina A , Ensaio de Imunoadsorção Enzimática/métodos , Imunoglobulina G , Sensibilidade e Especificidade , Imunoglobulina M , Anticorpos Antivirais
2.
Cir Cir ; 88(Suppl 2): 47-51, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33284266

RESUMO

En la última década, las úlceras marginales en pacientes tras un bypass gástrico se han convertido en un problema mucho más frecuente, y hoy en día aún no está clara su etiología. Se han descrito numerosos factores de riesgo, tales como un alto consumo de tabaco o de antiinflamatorios no esteroideos (AINE), entre otros. Presentamos el caso de una paciente con úlcera gástrica perforada en el remanente gástrico, con antecedente de bypass gástrico hace 4 años, tabaquismo y uso de AINE, por lo que se lleva a manejo laparoscópico con parche de Graham, adecuada evolución clínica y resolución de la sintomatología.In the last decade, marginal ulcers in post-gastric bypass patients have become a much more frequent problem. Multiple risk factors have been described, such as high consumption of tobacco or high consumption of nonsteroidal anti-inflammatory drugs (NSAIDs), among others. We present a case report of a patient with perforated gastric ulcer in the gastric pouch, with a history of gastric bypass 4 years ago associated with smoking and NSAIDs, so it is taken to laparoscopic management with Graham's patch management, adequate clinical evolution and resolution of symptoms.


Assuntos
Derivação Gástrica , Laparoscopia , Humanos , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA